[go: up one dir, main page]

GR1005093B - Αναλογα της σκυφοστατινης και ενδιαμεσα για την παραγωγη αυτων - Google Patents

Αναλογα της σκυφοστατινης και ενδιαμεσα για την παραγωγη αυτων

Info

Publication number
GR1005093B
GR1005093B GR20050100044A GR20050100044A GR1005093B GR 1005093 B GR1005093 B GR 1005093B GR 20050100044 A GR20050100044 A GR 20050100044A GR 20050100044 A GR20050100044 A GR 20050100044A GR 1005093 B GR1005093 B GR 1005093B
Authority
GR
Greece
Prior art keywords
scyphostatin
intermediates
production
analogues
diseases
Prior art date
Application number
GR20050100044A
Other languages
English (en)
Inventor
Εμμανουηλ Νικολαου Πιτσινος
Original Assignee
Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"
Εμμανουηλ Νικολαου Πιτσινος
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος", Εμμανουηλ Νικολαου Πιτσινος filed Critical Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"
Priority to GR20050100044A priority Critical patent/GR1005093B/el
Publication of GR1005093B publication Critical patent/GR1005093B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά στη σύνθεση της σκυφοστατίνης καθώς και αναλόγων αυτής. Ειδικότερα η παρούσα εφεύρεση αφορά στη σύνθεση του εποξυκυκλοεξενικού πυρήνα της σκυφοστατίνης και παραγώγων αυτού. Αυτές οι χημικές ενώσεις αναμένεται να είναι ισχυροί και εκλεκτικοί παρεμποδιστές του ενζύμου ουδέτερη σφιγκομυελινάση (N-SMase) και επομένως να έχουνφαρμακευτική χρήση για την αντιμετώπιση ασθενειώνόπως μόλυνση από τον ιό ανθρώπινης ανοσοανεπάρκειας (HIV), νευροεκφυλιστικές ασθένειες, φλεγμονώδεις ασθένειες, ισχαιμία, αποπληξία ή αρτηριοσκλήρυνση.
GR20050100044A 2005-02-01 2005-02-01 Αναλογα της σκυφοστατινης και ενδιαμεσα για την παραγωγη αυτων GR1005093B (el)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20050100044A GR1005093B (el) 2005-02-01 2005-02-01 Αναλογα της σκυφοστατινης και ενδιαμεσα για την παραγωγη αυτων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20050100044A GR1005093B (el) 2005-02-01 2005-02-01 Αναλογα της σκυφοστατινης και ενδιαμεσα για την παραγωγη αυτων

Publications (1)

Publication Number Publication Date
GR1005093B true GR1005093B (el) 2006-01-13

Family

ID=37502727

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20050100044A GR1005093B (el) 2005-02-01 2005-02-01 Αναλογα της σκυφοστατινης και ενδιαμεσα για την παραγωγη αυτων

Country Status (1)

Country Link
GR (1) GR1005093B (el)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555775A (zh) * 2013-09-13 2016-05-04 比亚尔-波特拉&Ca有限公司 制备用于治疗心血管疾病的药物及其中使用的中间体的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1234816A1 (de) * 2001-02-23 2002-08-28 Hans-Peter Dr. Deigner Scyphostatin-Analoga als SMase-Inhibitoren

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1234816A1 (de) * 2001-02-23 2002-08-28 Hans-Peter Dr. Deigner Scyphostatin-Analoga als SMase-Inhibitoren

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INOUE, MUNENORI ET AL: "Total synthesis of (+)-scyphostatin, A potent and specific inhibitor of neutral sphingomyelinase", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION , 43(32), 4207-4209 CODEN: ACIEF5; ISSN: 1433-7851, 2004, XP002346651 *
PITSINOS, EMMANUEL N. ET AL: "Synthesis and evaluation of three novel scyphostatin analogs as neutral sphingomyelinase inhibitors", CHEMBIOCHEM , 4(11), 1223-1225 CODEN: CBCHFX; ISSN: 1439-4227, 2003, XP002346652 *
TANAKA, MASAHIRO ET AL: "Structural Elucidation of Scyphostatin, an Inhibitor of Membrane-Bound Neutral Sphingomyelinase", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 119(33), 7871-7872 CODEN: JACSAT; ISSN: 0002-7863, 1997, XP002346653 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555775A (zh) * 2013-09-13 2016-05-04 比亚尔-波特拉&Ca有限公司 制备用于治疗心血管疾病的药物及其中使用的中间体的方法
US10329268B2 (en) 2013-09-13 2019-06-25 Bial-Portela & Ca, S.A. Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein

Similar Documents

Publication Publication Date Title
MY147732A (en) Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
WO2006136357A3 (de) Kristalline modifikationen des pyraclostrobins
WO2007022459A3 (en) Processes and intermediates
MX2007014172A (es) Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
ATE453670T1 (de) Acrylierte hyaluronsäure
MX2011011272A (es) Procesos e intermediarios.
PL2003120T3 (pl) Pochodne azapeptydu jako inhibitory proteazy HIV
UA97806C2 (ru) Бензиламины, способ их получения и их применения в качестве противовоспалительных средств
MX2009008925A (es) Compuestos de la formula (i) como inhibidores de proteasa de serina.
ATE444990T1 (de) Spritzbare akustikmassen
TW200611904A (en) Aza-bicyclononanes
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
PT2382198E (pt) Processos e intermediários para a preparação de um inibidor macrocíclico de protease do vhc
DK1670778T3 (da) Omlejrede pentanoler, en fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelsehæmmende
CY1112312T1 (el) Διεργασια για τον καθαρισμο της πρωτεϊνης δεσμευσης της ιl-18
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
MX2009010699A (es) Nuevos metodos.
PH12013501300A1 (en) Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
MY162786A (en) Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
WO2007115929A8 (de) Thiazolyl-dihydro-quinazoline
MX2007013872A (es) Procedimiento para la produccion de 4-bifenililazetidina-2-onas.
DK1831239T3 (da) Fremgangsmåde til fremstilling af 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-carboxylsyre-lambda-lacton og nøgle-mellemprodukter til denne fremgangsmåde

Legal Events

Date Code Title Description
PG Patent granted
ML Lapse due to non-payment of fees